Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American brain tumor consortium study

Neuro-Oncology

Volumn 6, Issue 1, 2004, Pages 33-37

  Prados, Michael D ^a   Yung, W K Alfred ^c   Fine, Howard A ^d   Greenberg, Harry S ^e   Junck, Larry ^e   Chang, Susan M ^a   Nicholas, M Kelly ^b   Robins, H Ian ^f   Mehta, Minesh P ^g   Fink, Karen L ^h   Jaeckle, Kurt A ⁱ   Kuhn, John ^j   Hess, Kenneth R ^c   Schold Jr , S Clifford ^k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k UNIVERSITY OF PITTSBURGH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LACTATE DEHYDROGENASE; STEROID; TEMOZOLOMIDE;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; FATIGUE; GLIOBLASTOMA; GRANULOCYTOPENIA; HUMAN; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; MEDICAL DOCUMENTATION; NEUROLOGIC EXAMINATION; NEUTROPENIA; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARMUSTINE; CONFIDENCE INTERVALS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NORTH AMERICA;

EID: 9144254455     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/S1152851703000309     Document Type: Article

References (12)

1. Fine, H.A. (1994) The basis for current treatment recommendations for malignant gliomas. J. Neurooncol. 20, 111-120.
2. Friedman, H.S., Johnson, S.P., Dong, Q., Schold, S.C., Rasheed, B.K., Bigner, S.H., Ali-Osman, F., Dolan, E., Colvin, O.M., Houghton, P., Germain, G., Drummond, J.T., Keir, S., Marcelli, S., Bigner, D.D., and Modrich, P. (1997) Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft [erratum in Cancer Res. 57, 4973, 1997] Cancer Res. 57, 2933-2936.
3. Hammond L.A., Eckardt, J.R., Kuhn, J., Rizzo, J., Johnson, T., Villalona-Calero, M., Tolcher, A., Von Hoff, D.D., and Rowinsky, E.K. (2000) A phase I and pharmacokinetic (PK) trial of 2 sequences of BCNU and temozolomide in patients with advanced solid tumors. Neuro-Oncol. 2, 267 (abstract 90).
4. Huncharek, M., and Muscat, J. (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patients. Anticancer Res. 18, 1303-1311.
5. NCI. National Cancer Institute (1999) Common Toxicity Criteria version 2.0. Available at https://webapps.ctep.nci.nih.gov/ctcv2/plsql/ctc000w$.startup.
6. Plowman, J., Waud, W.R., Koutsoukos, A.D., Rubinstein, L.V., Moore, T.D., and Grever, M.R. (1994) Preclinical antitumor activity of temozolomide in mice: Efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54, 3793-3799.
7. Rich, J., Reardon, D., Allen, D., Affronti, M., Carter, J., Edwards, S., Friedman, A., Gururangan, S., Herndon, J., Jackson, S., McLendon, R., Quinn, J., Tourt-Uhlig, S., Sampson, J., Bigner, D., Stafford-Fox, V., Zaknoen, S., and Friedman, H. (2001) Phase I/II trial of Gliadel plus Temodar for adult patients with recurrent high-grade glioma. Proc. Am. Soc. Clin. Oncol. 20, 75b (abstract 2051).
8. Schold, S.C. Jr., Kuhn, J.G., Chang, S.M., Bosik, M.E., Robins, H.I., Mehta, M.P., Spence, A.M., Fulton, D., Fink, K.L., and Prados, M.D. (2000) A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: A North American Brain Tumor Consortium study. Neuro-Oncol. 2, 34-39.
9. Stevens, M.F., and Newlands, E.S. (1993) From triazines and triazenes to temozolomide. Eur. J. Cancer 29A, 1045-1047.
10. Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K. (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572.
11. Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762-2771.
12. Yung, W.K., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593.